♥
ISIN : INE159A01016
NSE : GLAXO
BSE : 500660
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : 34.83
EPS (TTM) : 39.85
Price to Earning (P/E) : 82.70
Book Value : 105.47
Price to Bookvalue (P/B) : 27.31
Dividend Yield : 0 %
Return on Equity (ROE) : 33.43 %
Return on Capital Employed (ROCE) : 46.49 %
GlaxoSmithKline Pharmaceuticals Limited
ISIN : INE159A01016
NSE : GLAXO
BSE : 500660
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : 34.83
EPS (TTM) : 39.85
Price to Earning (P/E) : 82.70
Book Value : 105.47
Price to Bookvalue (P/B) : 27.31
Dividend Yield : 0 %
Return on Equity (ROE) : 33.43 %
Return on Capital Employed (ROCE) : 46.49 %
GlaxoSmithKline Pharmaceuticals share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 2299.95 - 2310.45 0.5 % |
| Low / High | 2262 - 2315.4 2.4 % |
| Trade Volume | 2,779 |
| 52 Week Low / High | 2218 - 3515.95 58.5 % |
-
YOU MAY ALSO LIKE
- Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - Share Market basics for beginners
Share Market jargons in simple terms - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Stock market course tutorial
Stock Market Investment Course explained in simple words.
CONSOLIDATED QUARTERLY RESULT FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 7451 | 9168.7 | 8023 | 7874.5 | 7616.6 | 9569.9 | 8052.6 | 9298 | 8146.5 | 10107.7 |
| Total Income | 7727.1 | 9388.4 | 8257.2 | 8151.1 | 7981 | 9852 | 8333.7 | 9596.3 | 8502.9 | 10453.1 |
| Total Expenditure | 5961.8 | 6599.4 | 5736 | 6177.1 | 6177.8 | 6675 | 5872 | 6725.4 | 5841.1 | 6890.6 |
| Other Income | 276.1 | 219.7 | 234.2 | 276.6 | 364.4 | 282.1 | 281.1 | 298.3 | 356.4 | 345.4 |
| Operating Profit | 1765.3 | 2789 | 2521.2 | 1974 | 1803.2 | 3177 | 2461.7 | 2870.9 | 2661.8 | 3562.5 |
| Interest | 6.8 | 3.9 | 0.9 | 6.5 | 2.8 | 4.3 | 3.2 | 7.7 | 3.7 | 2.7 |
| Exceptional Items | -113.7 | 104 | 173 | -1633.1 | 24 | 46.9 | ||||
| PBDT | 1758.5 | 2785.1 | 2406.6 | 2071.5 | 1973.4 | 3172.7 | 825.4 | 2887.2 | 2658.1 | 3606.7 |
| Depreciation | 158.2 | 163.6 | 164.1 | 171.8 | 163.6 | 181.1 | 171.1 | 181 | 164.1 | 168.6 |
| Profit Before Tax | 1600.3 | 2621.5 | 2242.5 | 1899.7 | 1809.8 | 2991.6 | 654.3 | 2706.2 | 2494 | 3438.1 |
| Tax | 438 | 687.3 | 596.9 | 565.4 | 487.3 | 816.5 | 197.1 | 761.4 | 670.7 | 913.1 |
| Profit After Tax | 1162.3 | 1934.2 | 1645.6 | 1334.3 | 1322.5 | 2175.1 | 457.2 | 1944.8 | 1823.3 | 2525 |
| Net Profit | 1192.8 | 1934.2 | 1645.6 | 1334.3 | 1322.5 | 2175.1 | 457.2 | 1944.8 | 1823.3 | 2525 |
| Equity Capital | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calculated EPS | 7.04 | 11.42 | 9.71 | 7.88 | 7.81 | 12.84 | 2.7 | 11.48 | 10.76 | 14.9 |
| Diluted Eps After Extraordinary Items | 6.86 | 11.42 | 9.71 | 7.88 | 7.81 | 12.84 | 2.7 | 11.48 | 10.76 | 14.91 |
| Diluted Eps Before Extraordinary Items | 6.86 | 11.42 | 9.71 | 7.88 | 7.81 | 12.84 | 2.7 | 11.48 | 10.76 | 14.91 |
STANDALONE QUARTERLY RESULT FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 7294.6 | 9056.1 | 7991.1 | 7821.6 | 7380.2 | 9533.8 | 8049.8 | 9108.7 | 8110 | 10000.5 |
| Total Income | 7572.5 | 9277.7 | 8227.1 | 8101.3 | 7748.2 | 9818.5 | 8333.2 | 9407.4 | 8468.5 | 10322.4 |
| Total Expenditure | 5815.3 | 6486.9 | 5713.1 | 6154 | 5967.7 | 6668 | 5874.7 | 6555.6 | 5815.8 | 6811 |
| Other Income | 277.9 | 221.6 | 236 | 279.7 | 368 | 284.7 | 283.4 | 298.7 | 358.5 | 321.9 |
| Operating Profit | 1757.2 | 2790.8 | 2514 | 1947.3 | 1780.5 | 3150.5 | 2458.5 | 2851.8 | 2652.7 | 3511.4 |
| Interest | 6.8 | 3.9 | 0.9 | 6.5 | 2.8 | 4.3 | 3.2 | 7.7 | 3.7 | 2.7 |
| Exceptional Items | -113.7 | 104 | 173 | -1633.1 | 24 | 46.9 | ||||
| PBDT | 1750.4 | 2786.9 | 2399.4 | 2044.8 | 1950.7 | 3146.2 | 822.2 | 2868.1 | 2649 | 3555.6 |
| Depreciation | 158.2 | 163.6 | 164.1 | 171.8 | 163.6 | 181.1 | 171.1 | 181 | 164.1 | 168.6 |
| Profit Before Tax | 1592.2 | 2623.3 | 2235.3 | 1873 | 1787.1 | 2965.1 | 651.1 | 2687.1 | 2484.9 | 3387 |
| Tax | 435.9 | 687.7 | 595 | 558.2 | 481.3 | 809.7 | 196.2 | 756.3 | 668.4 | 900.1 |
| Profit After Tax | 1156.3 | 1935.6 | 1640.3 | 1314.8 | 1305.8 | 2155.4 | 454.9 | 1930.8 | 1816.5 | 2486.9 |
| Net Profit | 1186.8 | 1935.6 | 1640.3 | 1314.8 | 1305.8 | 2155.4 | 454.9 | 1930.8 | 1816.5 | 2486.9 |
| Equity Capital | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 | 1694.1 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calculated EPS | 6.83 | 11.43 | 9.68 | 7.76 | 7.71 | 12.72 | 2.69 | 11.4 | 10.72 | 14.68 |
| Diluted Eps After Extraordinary Items | 6.83 | 11.42 | 9.68 | 7.77 | 7.71 | 12.72 | 2.69 | 11.39 | 10.72 | 14.68 |
| Diluted Eps Before Extraordinary Items | 6.83 | 11.42 | 9.68 | 7.77 | 7.71 | 12.72 | 2.69 | 11.39 | 10.72 | 14.68 |
CONSOLIDATED ANNUAL RESULT FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 32780.3 | 32517.2 | 34537.1 |
| Total Income | 33538.1 | 33523.8 | 35763 |
| Total Expenditure | 25161.5 | 24474.3 | 25450.2 |
| Other Income | 757.8 | 1006.6 | 1225.9 |
| Operating Profit | 8376.6 | 9049.5 | 10312.8 |
| Interest | 20 | 18.1 | 18 |
| Exceptional Items | 115.8 | -9.7 | -1436.1 |
| PBDT | 8472.4 | 9021.7 | 8858.7 |
| Depreciation | 681.9 | 657.7 | 696.8 |
| Profit Before Tax | 7790.5 | 8364 | 8161.9 |
| Tax | 3982.8 | 2287.6 | 2262.3 |
| Profit After Tax | 3807.7 | 6076.4 | 5899.6 |
| Net Profit | 16947.2 | 6106.9 | 5899.6 |
| Equity Capital | 1694.1 | 1694.1 | 1694.1 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Reserves | 24935.5 | 15718.7 | 16082.3 |
| Calculated EPS | 100.04 | 36.05 | 34.82 |
| Diluted Eps After Extraordinary Items | 22.48 | 36.05 | 34.83 |
| Diluted Eps Before Extraordinary Items | 22.48 | 36.05 | 34.83 |
STANDALONE ANNUAL RESULT FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 32175.1 | 32163.4 | 34072.5 |
| Total Income | 32937.3 | 33178.6 | 35307.3 |
| Total Expenditure | 24616.8 | 24169.3 | 25066 |
| Other Income | 762.2 | 1015.2 | 1234.8 |
| Operating Profit | 8320.5 | 9009.3 | 10241.3 |
| Interest | 19.9 | 18.1 | 18 |
| Exceptional Items | 115.8 | -9.7 | -1436.1 |
| PBDT | 8416.4 | 8981.5 | 8787.2 |
| Depreciation | 681.9 | 657.7 | 696.8 |
| Profit Before Tax | 7734.5 | 8323.8 | 8090.4 |
| Tax | 3968.7 | 2276.8 | 2243.5 |
| Profit After Tax | 3765.8 | 6047 | 5846.9 |
| Net Profit | 16905.3 | 6077.5 | 5846.9 |
| Equity Capital | 1694.1 | 1694.1 | 1694.1 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Reserves | 25082.1 | 15835.9 | 16146.8 |
| Calculated EPS | 22.23 | 35.69 | 34.51 |
| Diluted Eps After Extraordinary Items | 22.23 | 35.88 | 34.51 |
| Diluted Eps Before Extraordinary Items | 22.23 | 35.88 | 34.51 |
CONSOLIDATED PROFIT / LOSS FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 3198.86 Cr | 3598.33 Cr | 3568.12 Cr | 3453.71 Cr |
| Sales | 3169.47 Cr | 3584.39 Cr | 3542.78 Cr | 3441.77 Cr |
| Processing Charges / Service Income | 20.42 Cr | 12.71 Cr | 24.24 Cr | 10.49 Cr |
| Net Sales | 3198.86 Cr | 3278.03 Cr | 3251.72 Cr | 3453.71 Cr |
| Increase/Decrease in Stock | -39.43 Cr | 15.57 Cr | 68.96 Cr | -63.72 Cr |
| Raw Material Consumed | 1352.14 Cr | 1340.62 Cr | 1215.92 Cr | 1398.25 Cr |
| Opening Raw Materials | 76.48 Cr | 100.35 Cr | 107.11 Cr | 104.48 Cr |
| Purchases Raw Materials | 495.89 Cr | 617.94 Cr | 424.86 Cr | 547.97 Cr |
| Closing Raw Materials | 100.35 Cr | 107.11 Cr | 104.48 Cr | 107.28 Cr |
| Other Direct Purchases / Brought in cost | 880.11 Cr | 729.44 Cr | 788.43 Cr | 853.08 Cr |
| Power & Fuel Cost | 26.08 Cr | 27.83 Cr | 29.6 Cr | 29.64 Cr |
| Electricity & Power | 26.08 Cr | 27.83 Cr | 29.6 Cr | 29.64 Cr |
| Employee Cost | 614.69 Cr | 610.23 Cr | 594.99 Cr | 624.39 Cr |
| Salaries, Wages & Bonus | 563.61 Cr | 559.17 Cr | 541.72 Cr | 568.56 Cr |
| Contributions to EPF & Pension Funds | 24.51 Cr | 23.15 Cr | 21.59 Cr | 21.41 Cr |
| Workmen and Staff Welfare Expenses | 17.64 Cr | 19.37 Cr | 20.5 Cr | 15.67 Cr |
| Other Manufacturing Expenses | 106.55 Cr | 120.14 Cr | 99.05 Cr | 113.61 Cr |
| Repairs and Maintenance | 21.49 Cr | 22.02 Cr | 19.24 Cr | 20.67 Cr |
| General and Administration Expenses | 118.87 Cr | 144.08 Cr | 189.33 Cr | 190.5 Cr |
| Rent , Rates & Taxes | 41.48 Cr | 29.48 Cr | 66.07 Cr | 50.39 Cr |
| Insurance | 5.52 Cr | 5.35 Cr | 5.1 Cr | 7.93 Cr |
| Printing and stationery | 9.19 Cr | 11.53 Cr | 11.63 Cr | 16.47 Cr |
| Professional and legal fees | 11.78 Cr | 35.97 Cr | 22.83 Cr | 22.82 Cr |
| Traveling and conveyance | 46.88 Cr | 54.59 Cr | 75.93 Cr | 73.28 Cr |
| Selling and Distribution Expenses | 190.92 Cr | 200.23 Cr | 180.97 Cr | 184.22 Cr |
| Advertisement & Sales Promotion | 128.6 Cr | 128.33 Cr | 109.12 Cr | 109.36 Cr |
| Sales Commissions & Incentives | 19.9 Cr | 20.95 Cr | 19.47 Cr | 21.01 Cr |
| Freight and Forwarding | 42.43 Cr | 50.95 Cr | 52.37 Cr | 53.85 Cr |
| Miscellaneous Expenses | 133.71 Cr | 57.45 Cr | 68.62 Cr | 68.13 Cr |
| Loss on foreign exchange fluctuations | 5.88 Lk | 5.14 Cr | 9.91 Cr | 0 |
| Total Expenditure | 2503.53 Cr | 2516.15 Cr | 2447.44 Cr | 2545.02 Cr |
| Other Income | 110.58 Cr | 75.78 Cr | 100.66 Cr | 122.59 Cr |
| Interest Received | 110.58 Cr | 71.75 Cr | 69.81 Cr | 67.85 Cr |
| Profit on sale of Fixed Assets | 0 | 32.37 Lk | 2.78 Lk | 88.94 Lk |
| Profits on sale of Investments | 0 | 0 | 30.78 Cr | 48.78 Cr |
| Provision Written Back | 0 | 67,000 | 0 | 0 |
| Operating Profit | 805.91 Cr | 837.65 Cr | 904.95 Cr | 1031.28 Cr |
| Interest | 3.53 Cr | 2 Cr | 1.81 Cr | 1.8 Cr |
| Intereston Fixed deposits | 34.99 Lk | 25.91 Lk | 41.44 Lk | 22.4 Lk |
| PBDT | 802.38 Cr | 835.66 Cr | 903.14 Cr | 1029.48 Cr |
| Depreciation | 79.28 Cr | 68.19 Cr | 65.77 Cr | 69.68 Cr |
| Profit Before Taxation & Exceptional Items | 723.1 Cr | 767.47 Cr | 837.37 Cr | 959.8 Cr |
| Exceptional Income / Expenses | -172.6 Cr | 11.58 Cr | -96.79 Lk | -143.62 Cr |
| Profit Before Tax | 550.5 Cr | 779.05 Cr | 836.4 Cr | 816.19 Cr |
| Provision for Tax | 192.35 Cr | 398.28 Cr | 228.76 Cr | 226.23 Cr |
| Current Income Tax | 184.3 Cr | 219.74 Cr | 247.12 Cr | 237.59 Cr |
| Deferred Tax | 8.05 Cr | -9.4 Cr | -18.37 Cr | -11.36 Cr |
| Profit After Tax | 358.15 Cr | 380.77 Cr | 607.64 Cr | 589.96 Cr |
| Extra items | 0 | 1313.95 Cr | 3.04 Cr | 0 |
| Consolidated Net Profit | 358.15 Cr | 1694.72 Cr | 610.69 Cr | 589.96 Cr |
| Profit Balance B/F | 875.52 Cr | 556.04 Cr | 1742.54 Cr | 828.57 Cr |
| Appropriations | 1233.67 Cr | 2250.76 Cr | 2353.23 Cr | 1418.53 Cr |
| Other Appropriation | 677.62 Cr | 508.22 Cr | 1524.66 Cr | 542.1 Cr |
| Equity Dividend % | 300 | 900 | 320 | 320 |
| Earnings Per Share | 21.14 | 100.04 | 36.05 | 34.83 |
| Adjusted EPS | 21.14 | 100.04 | 36.05 | 34.83 |
STANDALONE PROFIT / LOSS FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 3193.74 Cr | 3217.51 Cr | 3532.74 Cr | 3738.16 Cr |
| Sales | 3160.15 Cr | 3190.08 Cr | 3497.8 Cr | 3716.85 Cr |
| Processing Charges / Service Income | 20.68 Cr | 13.32 Cr | 24.85 Cr | 11.09 Cr |
| Net Sales | 3193.74 Cr | 3217.51 Cr | 3216.34 Cr | 3407.25 Cr |
| Increase/Decrease in Stock | -27.53 Cr | 13.83 Cr | 67.24 Cr | -69.64 Cr |
| Raw Material Consumed | 1332.75 Cr | 1281.91 Cr | 1182.78 Cr | 1358.07 Cr |
| Opening Raw Materials | 76.48 Cr | 88.88 Cr | 95.28 Cr | 90.65 Cr |
| Purchases Raw Materials | 465.04 Cr | 558.86 Cr | 389.72 Cr | 513.39 Cr |
| Closing Raw Materials | 88.88 Cr | 95.28 Cr | 90.65 Cr | 99.04 Cr |
| Other Direct Purchases / Brought in cost | 880.11 Cr | 729.44 Cr | 788.43 Cr | 853.08 Cr |
| Power & Fuel Cost | 26.08 Cr | 27.83 Cr | 29.6 Cr | 29.64 Cr |
| Electricity & Power | 26.08 Cr | 27.83 Cr | 29.6 Cr | 29.64 Cr |
| Employee Cost | 614.69 Cr | 610.23 Cr | 594.99 Cr | 624.39 Cr |
| Salaries, Wages & Bonus | 563.61 Cr | 559.17 Cr | 541.72 Cr | 568.56 Cr |
| Contributions to EPF & Pension Funds | 24.51 Cr | 23.15 Cr | 21.59 Cr | 21.41 Cr |
| Workmen and Staff Welfare Expenses | 17.64 Cr | 19.37 Cr | 20.5 Cr | 15.67 Cr |
| Other Manufacturing Expenses | 106.53 Cr | 120.14 Cr | 99.05 Cr | 113.61 Cr |
| Repairs and Maintenance | 21.46 Cr | 22.02 Cr | 19.24 Cr | 20.67 Cr |
| General and Administration Expenses | 118.77 Cr | 143.99 Cr | 189.33 Cr | 190.48 Cr |
| Rent , Rates & Taxes | 41.44 Cr | 29.39 Cr | 66.07 Cr | 50.39 Cr |
| Insurance | 5.52 Cr | 5.35 Cr | 5.1 Cr | 7.93 Cr |
| Printing and stationery | 9.19 Cr | 11.53 Cr | 11.63 Cr | 16.47 Cr |
| Professional and legal fees | 11.73 Cr | 35.97 Cr | 22.83 Cr | 22.82 Cr |
| Traveling and conveyance | 46.88 Cr | 54.59 Cr | 75.93 Cr | 73.28 Cr |
| Selling and Distribution Expenses | 190.92 Cr | 200.23 Cr | 180.97 Cr | 184.22 Cr |
| Advertisement & Sales Promotion | 128.6 Cr | 128.33 Cr | 109.12 Cr | 109.36 Cr |
| Sales Commissions & Incentives | 19.9 Cr | 20.95 Cr | 19.47 Cr | 21.01 Cr |
| Freight and Forwarding | 42.43 Cr | 50.95 Cr | 52.37 Cr | 53.85 Cr |
| Miscellaneous Expenses | 136.57 Cr | 63.53 Cr | 72.95 Cr | 75.82 Cr |
| Loss on disposal of fixed assets(net) | 5.88 Lk | 0 | 0 | 0 |
| Loss on foreign exchange fluctuations | 0 | 5.14 Cr | 8.84 Cr | 0 |
| Total Expenditure | 2498.78 Cr | 2461.68 Cr | 2416.92 Cr | 2506.6 Cr |
| Other Income | 110.19 Cr | 76.22 Cr | 101.51 Cr | 123.48 Cr |
| Interest Received | 110.19 Cr | 72.19 Cr | 70.66 Cr | 68.86 Cr |
| Profit on sale of Fixed Assets | 0 | 32.37 Lk | 2.78 Lk | 88.94 Lk |
| Profits on sale of Investments | 0 | 0 | 30.78 Cr | 48.78 Cr |
| Operating Profit | 805.15 Cr | 832.04 Cr | 900.94 Cr | 1024.13 Cr |
| Interest | 3.53 Cr | 1.99 Cr | 1.81 Cr | 1.8 Cr |
| Intereston Fixed deposits | 34.99 Lk | 25.28 Lk | 41.3 Lk | 22.4 Lk |
| PBDT | 801.62 Cr | 830.05 Cr | 899.13 Cr | 1022.33 Cr |
| Depreciation | 79.28 Cr | 68.19 Cr | 65.77 Cr | 69.68 Cr |
| Profit Before Taxation & Exceptional Items | 722.33 Cr | 761.87 Cr | 833.36 Cr | 952.65 Cr |
| Exceptional Income / Expenses | -172.6 Cr | 11.58 Cr | -96.79 Lk | -143.62 Cr |
| Profit Before Tax | 549.74 Cr | 773.44 Cr | 832.39 Cr | 809.04 Cr |
| Provision for Tax | 192.17 Cr | 396.87 Cr | 227.69 Cr | 224.35 Cr |
| Current Income Tax | 184.3 Cr | 219.43 Cr | 246.05 Cr | 235.71 Cr |
| Deferred Tax | 7.87 Cr | -10.49 Cr | -18.37 Cr | -11.36 Cr |
| Profit After Tax | 357.57 Cr | 376.58 Cr | 604.71 Cr | 584.69 Cr |
| Extra items | 0 | 1313.95 Cr | 3.04 Cr | 0 |
| Consolidated Net Profit | 357.57 Cr | 1690.53 Cr | 607.75 Cr | 584.69 Cr |
| Profit Balance B/F | 882.77 Cr | 562.71 Cr | 1745.02 Cr | 828.12 Cr |
| Appropriations | 1240.34 Cr | 2253.24 Cr | 2352.77 Cr | 1412.81 Cr |
| Other Appropriation | 677.62 Cr | 508.22 Cr | 1524.66 Cr | 542.1 Cr |
| Equity Dividend % | 300 | 900 | 320 | 320 |
| Earnings Per Share | 21.11 | 22.23 | 35.7 | 34.51 |
| Adjusted EPS | 21.11 | 22.23 | 35.7 | 34.51 |
CONSOLIDATED CASH FLOW FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 723.1 Cr | 2475.65 Cr | 841.49 Cr | 959.8 Cr |
| Adjustment | -25.64 Cr | -1636.48 Cr | -40 Cr | -45.13 Cr |
| Changes In working Capital | 45.76 Cr | 119.87 Cr | -45.75 Cr | 61.02 Cr |
| Cash Flow after changes in Working Capital | 743.22 Cr | 959.04 Cr | 755.75 Cr | 975.7 Cr |
| Cash Flow from Operating Activities | 577.92 Cr | 810.75 Cr | 484.22 Cr | 582.02 Cr |
| Cash Flow from Investing Activities | 418.59 Cr | -405.51 Cr | 807.85 Cr | 8.71 Cr |
| Cash Flow from Financing Activitie | -696.14 Cr | -524.24 Cr | -1543.32 Cr | -561.5 Cr |
| Net Cash Inflow / Outflow | 300.38 Cr | -119 Cr | -251.25 Cr | 29.23 Cr |
| Opening Cash & Cash Equivalents | 104.81 Cr | 405.19 Cr | 286.19 Cr | 34.94 Cr |
| Closing Cash & Cash Equivalent | 405.19 Cr | 286.19 Cr | 34.94 Cr | 64.17 Cr |
STANDALONE CASH FLOW FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 722.33 Cr | 2470.04 Cr | 837.49 Cr | 952.65 Cr |
| Adjustment | -25.25 Cr | -1636.93 Cr | -40.86 Cr | -46.14 Cr |
| Changes In working Capital | 63.03 Cr | 134.89 Cr | -39.02 Cr | 64.55 Cr |
| Cash Flow after changes in Working Capital | 760.11 Cr | 968 Cr | 757.61 Cr | 971.06 Cr |
| Cash Flow from Operating Activities | 594.86 Cr | 819.79 Cr | 487.94 Cr | 578.94 Cr |
| Cash Flow from Investing Activities | 408.15 Cr | -419.66 Cr | 805.2 Cr | 14.97 Cr |
| Cash Flow from Financing Activitie | -696.14 Cr | -524.24 Cr | -1544.18 Cr | -561.5 Cr |
| Net Cash Inflow / Outflow | 306.87 Cr | -124.11 Cr | -251.05 Cr | 32.41 Cr |
| Opening Cash & Cash Equivalents | 98.03 Cr | 404.9 Cr | 280.79 Cr | 29.74 Cr |
| Closing Cash & Cash Equivalent | 404.9 Cr | 280.79 Cr | 29.74 Cr | 62.15 Cr |
CONSOLIDATED BALANCE SHEET FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 169.41 Cr | 169.41 Cr | 169.41 Cr | 169.41 Cr |
| Equity - Authorised | 180 Cr | 180 Cr | 180 Cr | 180 Cr |
| Equity - Issued | 169.42 Cr | 169.42 Cr | 169.42 Cr | 169.42 Cr |
| Equity Paid Up | 169.41 Cr | 169.41 Cr | 169.41 Cr | 169.41 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | 1329.67 Cr | 2493.55 Cr | 1573.54 Cr | 1617.24 Cr |
| Capital Reserves | 1.71 Cr | -19.07 Cr | -19.07 Cr | -19.07 Cr |
| Profit & Loss Account Balance | 556.04 Cr | 1742.54 Cr | 828.57 Cr | 876.44 Cr |
| General Reserves | 778.5 Cr | 778.5 Cr | 778.5 Cr | 778.5 Cr |
| Reserve excluding Revaluation Reserve | 1329.67 Cr | 2493.55 Cr | 1573.54 Cr | 1617.24 Cr |
| Shareholder's Funds | 1499.08 Cr | 2662.96 Cr | 1741.27 Cr | 1777.64 Cr |
| Deferred Tax Assets / Liabilities | -103.13 Cr | -113.15 Cr | -133.55 Cr | -146.31 Cr |
| Deferred Tax Assets | 118.7 Cr | 132.03 Cr | 151.74 Cr | 163.45 Cr |
| Deferred Tax Liability | 15.57 Cr | 18.89 Cr | 18.2 Cr | 17.14 Cr |
| Other Long Term Liabilities | 22.31 Cr | 9.68 Cr | 4.14 Cr | 6.57 Cr |
| Long Term Provisions | 259.5 Cr | 262.21 Cr | 254.8 Cr | 247.46 Cr |
| Total Non-Current Liabilities | 178.68 Cr | 158.74 Cr | 125.4 Cr | 107.72 Cr |
| Trade Payables | 464.47 Cr | 570.55 Cr | 427.79 Cr | 625.41 Cr |
| Sundry Creditors | 464.47 Cr | 570.55 Cr | 427.79 Cr | 625.41 Cr |
| Other Current Liabilities | 450.11 Cr | 503.7 Cr | 184.59 Cr | 207.44 Cr |
| Advances received from customers | 4.91 Cr | 4.35 Cr | 7.08 Cr | 7.55 Cr |
| Short Term Provisions | 417.9 Cr | 624.18 Cr | 714 Cr | 692.1 Cr |
| Provision for Tax | 163.72 Cr | 296.2 Cr | 296.2 Cr | 298.58 Cr |
| Provision for post retirement benefits | 3.36 Cr | 3.42 Cr | 4.48 Cr | 4.78 Cr |
| Total Current Liabilities | 1332.47 Cr | 1698.43 Cr | 1326.37 Cr | 1524.95 Cr |
| Total Liabilities | 3010.23 Cr | 4520.13 Cr | 3193.04 Cr | 3410.31 Cr |
| Gross Block | 614.71 Cr | 606.4 Cr | 649.79 Cr | 680.87 Cr |
| Less: Accumulated Depreciation | 230.44 Cr | 275.52 Cr | 320.89 Cr | 360.52 Cr |
| Less: Impairment of Assets | 0 | 1.44 Cr | 0 | 0 |
| Net Block | 384.27 Cr | 329.44 Cr | 328.9 Cr | 320.36 Cr |
| Capital Work in Progress | 13.21 Cr | 30.5 Cr | 20.31 Cr | 13.93 Cr |
| Non Current Investments | 1.35 Cr | 1.21 Cr | 0 | 0 |
| Long Term Investment | 1.35 Cr | 1.21 Cr | 0 | 0 |
| Unquoted | 1.35 Cr | 1.21 Cr | 0 | 0 |
| Long Term Loans & Advances | 401.71 Cr | 445.49 Cr | 342.64 Cr | 275.44 Cr |
| Other Non Current Assets | 7.03 Cr | 5.45 Cr | 5.86 Cr | 1.24 Cr |
| Total Non-Current Assets | 807.58 Cr | 812.1 Cr | 698.77 Cr | 611.89 Cr |
| Currents Investments | 0 | 365.59 Cr | 518.29 Cr | 813.22 Cr |
| Quoted | 0 | 365.59 Cr | 518.29 Cr | 813.22 Cr |
| Unquoted | 1.35 Cr | 1.21 Cr | 0 | 0 |
| Inventories | 546.7 Cr | 534.7 Cr | 459.97 Cr | 525.05 Cr |
| Raw Materials | 100.35 Cr | 107.11 Cr | 104.48 Cr | 107.28 Cr |
| Work-in Progress | 1.3 Cr | 87.62 Lk | 95.19 Lk | 80.67 Lk |
| Finished Goods | 127.88 Cr | 150.56 Cr | 100.83 Cr | 99.12 Cr |
| Stores and Spare | 3.79 Cr | 3.88 Cr | 3.85 Cr | 4 Cr |
| Sundry Debtors | 215.6 Cr | 205.24 Cr | 192.38 Cr | 222.06 Cr |
| Debtors more than Six months | 0 | 25.66 Cr | 16.75 Cr | 15.52 Cr |
| Debtors Others | 235.68 Cr | 199.81 Cr | 188.5 Cr | 219.99 Cr |
| Cash and Bank | 1157.98 Cr | 2484.51 Cr | 1155.93 Cr | 1063.22 Cr |
| Balances at Bank | 1157.98 Cr | 2484.51 Cr | 1155.93 Cr | 1063.22 Cr |
| Other Current Assets | 224.74 Cr | 89.6 Cr | 155.48 Cr | 150.19 Cr |
| Interest accrued on Investments | 7.51 Cr | 7.64 Cr | 14.08 Cr | 9.01 Cr |
| Prepaid Expenses | 13.5 Cr | 13.93 Cr | 14.96 Cr | 20.62 Cr |
| Short Term Loans and Advances | 57.64 Cr | 28.4 Cr | 12.22 Cr | 24.68 Cr |
| Advances recoverable in cash or in kind | 11.29 Cr | 18.67 Cr | 7.84 Cr | 9.18 Cr |
| Total Current Assets | 2202.65 Cr | 3708.03 Cr | 2494.26 Cr | 2798.42 Cr |
| Net Current Assets (Including Current Investments) | 870.18 Cr | 2009.6 Cr | 1167.89 Cr | 1273.47 Cr |
| Total Assets | 3010.23 Cr | 4520.13 Cr | 3193.04 Cr | 3410.31 Cr |
| Contingent Liabilities | 168.48 Cr | 354.78 Cr | 353.87 Cr | 378.58 Cr |
| Total Debt | 2.4 Lk | 0 | 0 | 0 |
| Book Value | 88.49 | 157.19 | 102.89 | 105.47 |
| Adjusted Book Value | 88.49 | 157.19 | 102.89 | 105.47 |
STANDALONE BALANCE SHEET FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 169.41 Cr | 169.41 Cr | 169.41 Cr | 169.41 Cr |
| Equity - Authorised | 180 Cr | 180 Cr | 180 Cr | 180 Cr |
| Equity - Issued | 169.42 Cr | 169.42 Cr | 169.42 Cr | 169.42 Cr |
| Equity Paid Up | 169.41 Cr | 169.41 Cr | 169.41 Cr | 169.41 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | 1348.53 Cr | 2508.21 Cr | 1585.27 Cr | 1623.69 Cr |
| Capital Reserves | 1.66 Cr | -19.12 Cr | -19.12 Cr | -19.12 Cr |
| Profit & Loss Account Balance | 562.71 Cr | 1745.02 Cr | 828.12 Cr | 870.71 Cr |
| General Reserves | 790.74 Cr | 790.74 Cr | 790.74 Cr | 790.74 Cr |
| Reserve excluding Revaluation Reserve | 1348.53 Cr | 2508.21 Cr | 1585.27 Cr | 1623.69 Cr |
| Shareholder's Funds | 1517.93 Cr | 2677.62 Cr | 1753 Cr | 1784.09 Cr |
| Deferred Tax Assets / Liabilities | -101.67 Cr | -112.78 Cr | -133.18 Cr | -145.95 Cr |
| Deferred Tax Assets | 117.24 Cr | 131.67 Cr | 151.38 Cr | 163.08 Cr |
| Deferred Tax Liability | 15.57 Cr | 18.89 Cr | 18.2 Cr | 17.14 Cr |
| Other Long Term Liabilities | 22.29 Cr | 9.67 Cr | 4.12 Cr | 6.55 Cr |
| Long Term Provisions | 258.25 Cr | 260.96 Cr | 253.55 Cr | 246.21 Cr |
| Total Non-Current Liabilities | 178.87 Cr | 157.84 Cr | 124.49 Cr | 106.82 Cr |
| Trade Payables | 446.33 Cr | 546.63 Cr | 418.56 Cr | 613.24 Cr |
| Sundry Creditors | 446.33 Cr | 546.63 Cr | 418.56 Cr | 613.24 Cr |
| Other Current Liabilities | 433.09 Cr | 503.54 Cr | 184.47 Cr | 205.6 Cr |
| Advances received from customers | 4.91 Cr | 4.35 Cr | 7.08 Cr | 7.55 Cr |
| Short Term Provisions | 417.9 Cr | 624.18 Cr | 714 Cr | 692.1 Cr |
| Provision for Tax | 163.72 Cr | 296.2 Cr | 296.2 Cr | 298.58 Cr |
| Provision for post retirement benefits | 3.36 Cr | 3.42 Cr | 4.48 Cr | 4.78 Cr |
| Total Current Liabilities | 1297.32 Cr | 1674.35 Cr | 1317.03 Cr | 1510.94 Cr |
| Total Liabilities | 2994.12 Cr | 4509.81 Cr | 3194.52 Cr | 3401.85 Cr |
| Gross Block | 614.71 Cr | 606.4 Cr | 649.79 Cr | 663.26 Cr |
| Less: Accumulated Depreciation | 230.44 Cr | 275.52 Cr | 320.89 Cr | 342.91 Cr |
| Less: Impairment of Assets | 0 | 1.44 Cr | 0 | 0 |
| Net Block | 384.27 Cr | 329.44 Cr | 328.9 Cr | 320.36 Cr |
| Capital Work in Progress | 13.21 Cr | 30.5 Cr | 20.31 Cr | 13.93 Cr |
| Non Current Investments | 25.82 Cr | 25.68 Cr | 24.49 Cr | 24.49 Cr |
| Long Term Investment | 25.82 Cr | 25.68 Cr | 24.49 Cr | 24.49 Cr |
| Unquoted | 48.94 Cr | 48.8 Cr | 47.61 Cr | 47.61 Cr |
| Long Term Loans & Advances | 392.45 Cr | 448.04 Cr | 347.22 Cr | 275.12 Cr |
| Other Non Current Assets | 7.03 Cr | 5.44 Cr | 5.84 Cr | 1.22 Cr |
| Total Non-Current Assets | 822.8 Cr | 839.1 Cr | 727.8 Cr | 636.01 Cr |
| Currents Investments | 0 | 365.59 Cr | 518.29 Cr | 813.22 Cr |
| Quoted | 0 | 365.59 Cr | 518.29 Cr | 813.22 Cr |
| Unquoted | 48.94 Cr | 48.8 Cr | 47.61 Cr | 47.61 Cr |
| Inventories | 523.34 Cr | 512.71 Cr | 437.7 Cr | 514.3 Cr |
| Raw Materials | 88.88 Cr | 95.28 Cr | 90.65 Cr | 99.04 Cr |
| Work-in Progress | 1.06 Cr | 72.86 Lk | 40.2 Lk | 80.67 Lk |
| Finished Goods | 116.22 Cr | 140.55 Cr | 92.94 Cr | 96.6 Cr |
| Stores and Spare | 3.79 Cr | 3.88 Cr | 3.85 Cr | 4 Cr |
| Sundry Debtors | 215.6 Cr | 205.24 Cr | 192.38 Cr | 222.06 Cr |
| Debtors more than Six months | 0 | 25.66 Cr | 16.75 Cr | 15.52 Cr |
| Debtors Others | 235.68 Cr | 199.81 Cr | 188.5 Cr | 219.99 Cr |
| Cash and Bank | 1157.68 Cr | 2479.11 Cr | 1150.73 Cr | 1061.2 Cr |
| Balances at Bank | 1157.68 Cr | 2479.11 Cr | 1150.73 Cr | 1061.2 Cr |
| Other Current Assets | 218.22 Cr | 79.66 Cr | 155.4 Cr | 130.39 Cr |
| Interest accrued on Investments | 7.5 Cr | 7.63 Cr | 14.08 Cr | 9.01 Cr |
| Prepaid Expenses | 13.5 Cr | 12.77 Cr | 13.81 Cr | 19.46 Cr |
| Short Term Loans and Advances | 56.48 Cr | 28.39 Cr | 12.22 Cr | 24.68 Cr |
| Advances recoverable in cash or in kind | 10.14 Cr | 18.67 Cr | 7.84 Cr | 9.18 Cr |
| Total Current Assets | 2171.33 Cr | 3670.71 Cr | 2466.72 Cr | 2765.84 Cr |
| Net Current Assets (Including Current Investments) | 874.01 Cr | 1996.36 Cr | 1149.69 Cr | 1254.9 Cr |
| Total Assets | 2994.12 Cr | 4509.81 Cr | 3194.52 Cr | 3401.85 Cr |
| Contingent Liabilities | 165.22 Cr | 128.7 Cr | 350.59 Cr | 375.4 Cr |
| Total Debt | 2.4 Lk | 0 | 0 | 0 |
| Book Value | 89.6 | 0 | 103.58 | 105.85 |
| Adjusted Book Value | 89.6 | 158.06 | 103.58 | 105.85 |
FINANCIAL RATIOS (CONSOLIDATED) FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 21.14 | 100.04 | 36.05 | 34.83 |
| CEPS(Rs) | 25.82 | 26.5 | 39.75 | 38.94 |
| DPS(Rs) | 30 | 90 | 32 | 32 |
| Book NAV/Share(Rs) | 88.49 | 157.19 | 102.89 | 105.47 |
| Tax Rate(%) | 34.94 | 51.12 | 27.35 | 27.72 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 21.74 | 21.17 | 22.54 | 26.31 |
| EBIT Margin(%) | 17.32 | 21.71 | 23.49 | 23.68 |
| Pre Tax Margin(%) | 17.21 | 21.65 | 23.44 | 23.63 |
| PAT Margin (%) | 11.2 | 10.58 | 17.03 | 17.08 |
| Cash Profit Margin (%) | 13.67 | 12.48 | 18.87 | 19.1 |
| Performance Ratios | ||||
| ROA(%) | 11.87 | 10.11 | 15.76 | 17.87 |
| ROE(%) | 21.58 | 18.39 | 27.58 | 33.43 |
| ROCE(%) | 33.38 | 37.72 | 38.06 | 46.49 |
| Asset Turnover(x) | 1.06 | 0.96 | 0.93 | 1.05 |
| Sales/Fixed Asset(x) | 3.1 | 5.96 | 5.75 | 5.25 |
| Working Capital/Sales(x) | 3.68 | 1.79 | 3.06 | 2.71 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.32 | 0.17 | 0.17 | 0.19 |
| Receivable days | 17.99 | 21.34 | 20.34 | 21.9 |
| Inventory Days | 58.75 | 54.85 | 50.87 | 52.05 |
| Payable days | 62.3 | 139.5 | 143.05 | 144.03 |
| Valuation Parameters | ||||
| PER(x) | 68.13 | 16.62 | 36.73 | 55.8 |
| PCE(x) | 55.78 | 62.75 | 33.31 | 49.9 |
| Price/Book(x) | 16.28 | 10.58 | 12.87 | 18.42 |
| Yield(%) | 2.08 | 5.41 | 2.42 | 1.65 |
| EV/Net Sales(x) | 7.27 | 7.84 | 6.54 | 9.22 |
| EV/Core EBITDA(x) | 28.84 | 30.67 | 23.51 | 30.89 |
| EV/EBIT(x) | 41.95 | 32.89 | 25.38 | 38.94 |
| EV/CE(x) | 7.72 | 5.68 | 6.66 | 17.92 |
| M Cap / Sales | 7.63 | 8.59 | 6.9 | 9.53 |
| Growth Ratio | ||||
| Net Sales Growth(%) | -0.79 | 12.05 | -0.8 | 6.21 |
| Core EBITDA Growth(%) | 9.46 | 18.19 | 8.03 | 13.96 |
| EBIT Growth(%) | 77.52 | 70.71 | 7.32 | -2.41 |
| PAT Growth(%) | 284.26 | 32.55 | 59.58 | -2.91 |
| EPS Growth(%) | 284.26 | 373.19 | -63.97 | -3.39 |
| Financial Stability Ratios | ||||
| Current Ratio(x) | 1.65 | 2.18 | 1.88 | 1.84 |
| Quick Ratio(x) | 1.24 | 1.87 | 1.53 | 1.49 |
| Interest Cover(x) | 156.89 | 391.29 | 462.54 | 454.77 |
FINANCIAL RATIOS (STANDALONE) FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 21.11 | 22.23 | 35.7 | 34.51 |
| CEPS(Rs) | 25.79 | 26.25 | 39.58 | 38.63 |
| DPS(Rs) | 30 | 90 | 32 | 32 |
| Book NAV/Share(Rs) | 89.6 | 158.06 | 103.58 | 105.85 |
| Tax Rate(%) | 34.96 | 51.31 | 27.35 | 27.73 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 21.76 | 23.49 | 22.63 | 24.09 |
| EBIT Margin(%) | 17.32 | 24.1 | 23.61 | 21.69 |
| Pre Tax Margin(%) | 17.21 | 24.04 | 23.56 | 21.64 |
| PAT Margin (%) | 11.2 | 11.7 | 17.12 | 15.64 |
| Cash Profit Margin (%) | 13.68 | 13.82 | 18.98 | 17.51 |
| Performance Ratios | ||||
| ROA(%) | 11.89 | 10.04 | 15.7 | 17.73 |
| ROE(%) | 21.3 | 18.04 | 27.29 | 32.96 |
| ROCE(%) | 32.95 | 37.15 | 37.66 | 45.85 |
| Asset Turnover(x) | 1.06 | 0.86 | 0.92 | 1.13 |
| Sales/Fixed Asset(x) | 3.09 | 5.33 | 5.69 | 5.76 |
| Working Capital/Sales(x) | 3.65 | 1.61 | 3.07 | 2.98 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.32 | 0.19 | 0.18 | 0.17 |
| Receivable days | 18.02 | 23.87 | 20.54 | 20.23 |
| Inventory Days | 57.51 | 58.77 | 49.1 | 46.48 |
| Payable days | 61.2 | 140.09 | 142.2 | 146.15 |
| Valuation Parameters | ||||
| PER(x) | 68.24 | 74.81 | 37.1 | 56.3 |
| PCE(x) | 55.86 | 63.34 | 33.46 | 50.3 |
| Price/Book(x) | 16.08 | 10.52 | 12.78 | 18.36 |
| Yield(%) | 2.08 | 5.41 | 2.42 | 1.65 |
| EV/Net Sales(x) | 7.28 | 7.99 | 6.62 | 9.35 |
| EV/Core EBITDA(x) | 28.87 | 30.88 | 23.62 | 31.11 |
| EV/EBIT(x) | 42.01 | 33.13 | 25.51 | 39.29 |
| EV/CE(x) | 7.76 | 5.7 | 6.66 | 17.86 |
| M Cap / Sales | 7.64 | 8.76 | 6.97 | 9.66 |
| Growth Ratio | ||||
| Net Sales Growth(%) | -0.96 | 10.17 | -0.04 | 5.94 |
| Core EBITDA Growth(%) | 9.39 | 17.53 | 8.28 | 13.67 |
| EBIT Growth(%) | 68.25 | 69.77 | 7.58 | -2.8 |
| PAT Growth(%) | 224.91 | 31.35 | 60.58 | -3.31 |
| EPS Growth(%) | 224.91 | 31.35 | 60.58 | -3.31 |
| Financial Stability Ratios | ||||
| Current Ratio(x) | 1.67 | 2.19 | 1.87 | 1.83 |
| Quick Ratio(x) | 1.27 | 1.89 | 1.54 | 1.49 |
| Interest Cover(x) | 156.67 | 389.7 | 460.68 | 450.79 |
SHARE HOLDING PATTERN FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Date | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| FII % | 2.16 | 2.17 | 2.28 | 2.28 | 2.41 | 2.50 | 2.93 | 3.48 | 4.02 | 4.36 |
| DII % | 0.08 | 0.06 | 0.02 | 0.01 | 0.01 | 0.03 | 0.10 | 0.12 | 0.11 | 0.07 |
| Public % | 12.19 | 12.29 | 12.43 | 12.43 | 12.34 | 12.49 | 13.43 | 13.62 | 13.48 | 13.30 |
PEER COMPARISON FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
CORPORATE ACTIONS FOR GLAXOSMITHKLINE PHARMACEUTICALS
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 07-Nov-2024 | Dividend - Interim Dividend | |
| BSE 24-Oct-2024 | Board Meeting - Interim Dividend & Quarterly Results | 29-Oct-2024 |
| BSE 18-Jul-2024 | Board Meeting - Quarterly Results | 02-Aug-2024 |
| BSE 31-May-2024 | Dividend - Rs.32.0000 per share(320%)Final Dividend | |
| BSE 19-Apr-2024 | Board Meeting - Audited Results & Final Dividend | 17-May-2024 |
| BSE 04-Jan-2024 | Board Meeting - Quarterly Results | 12-Feb-2024 |
| BSE 04-Oct-2023 | Board Meeting - Quarterly Results | 09-Nov-2023 |
| BSE 30-Jun-2023 | Board Meeting - Quarterly Results | 26-Jul-2023 |
| BSE 17-May-2023 | Dividend - Rs.32.0000 per share(320%)Final Dividend | |
| BSE 03-May-2023 | Board Meeting - Final Dividend & Audited Results | 17-May-2023 |
| BSE 11-Jan-2023 | Board Meeting - Quarterly Results | 07-Feb-2023 |
| BSE 31-Oct-2022 | Board Meeting - Quarterly Results | 11-Nov-2022 |
| BSE 28-Jun-2022 | Board Meeting - Quarterly Results | 25-Jul-2022 |
| BSE 16-May-2022 | Dividend - Rs.60.0000 per share(600%)Special Dividend | |
| BSE 16-May-2022 | AGM - Inter alia, approved: 1. Dividend The Board has recommended a dividend of Rs. 90/- (including special dividend of Rs. 60) per equity share on face value of Rs.10 each for the year ended 31 st March 2022, subject to approval of members at 97th Annual General Meeting to be held on Tuesday, 26th July, 2022. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regula... | 26-Jul-2022 |
| BSE 02-May-2022 | Board Meeting - Audited Results & Dividend | 16-May-2022 |
| BSE 28-Dec-2021 | Board Meeting - Quarterly Results | 07-Feb-2022 |
| BSE 27-Sep-2021 | Board Meeting - Quarterly Results | 29-Oct-2021 |
CORPORATE ANNOUNCEMENTS FOR GLAXOSMITHKLINE PHARMACEUTICALS
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 30-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under Regulation 39 |
| BSE 30-Oct-2024 | General Announcements FILE | Outcome Of Meeting outcome of Meeting |
| BSE 30-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Transcript |
| BSE 30-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication New paper publication |
| BSE 30-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication New paper publication |
| BSE 29-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Outcome |
| BSE 29-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Dividend Updates Dividend |
| BSE 29-Oct-2024 | Outcome FILE | Corporate Action-Board approves Dividend Dividend |
| BSE 29-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release |
| BSE 29-Oct-2024 | Outcome FILE | Un Audited Financials Results For Quarter & Half Year Ended 30Th September 2024 outcome of meeting |
| BSE 29-Oct-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Outcome of Meeting |
| BSE 28-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under Regulation 39 |
| BSE 24-Oct-2024 | Intimation FILE | Record Date Record Date for Interim Dividend |
| BSE 24-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Schedule of Analyst / Institutional Investor Meetings under the Listing Regulations |
| BSE 24-Oct-2024 | Intimation FILE | Board Meeting Intimation for Board Meeting GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve Unaudited Financial Results for quarter & half year ended 30th September 2024 and to consider the declaration of interim dividend (if any) |
| BSE 22-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under Regulation 39 |
| BSE 16-Oct-2024 | General Announcements FILE | Disclosure Under Regulation 30 Disclosure under Regulation 30 |
| BSE 03-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) |
| BSE 03-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under Regulation 39 |
| BSE 01-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under Regulation 39 |
| BSE 26-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under Regulation 39 |
| BSE 25-Sep-2024 | Intimation FILE | Closure of Trading Window Trading Window Closure |
| BSE 24-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under Regulation 39 |
| BSE 18-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation under regulation 39 |
| BSE 16-Sep-2024 | General Announcements FILE | Disclosure Under Regulation 30 Disclosure under Regulation 30 |
| BSE 03-Sep-2024 | General Announcements FILE | Disclosure Under Clause 30 Disclosure under clause 30 |
| BSE 03-Sep-2024 | General Announcements FILE | Disclosure Under Clause 30 Disclosure under clause 30 |
| BSE 03-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Advance intimation under Regulation 39 |
| BSE 02-Sep-2024 | General Announcements FILE | Disclosure Under Regulation 30 Disclosure under Regulation 30 |
| BSE 31-Aug-2024 | General Announcements FILE | Disclosure Under Regulation 30 Disclosure under Regulation 30 |
INSIDER TRADING FOR GLAXOSMITHKLINE PHARMACEUTICALS
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Insider trading details found | |||
BULK BLOCK DEALS FOR GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 17-Oct-2022 | Sell BLOCK | 80,615 @ 1378.65 | ISHARES CORE EMERGING MARKETS MAURITIUS CO |
| BSE 17-Oct-2022 | Buy BLOCK | 80,615 @ 1378.65 | ISHARES CORE MSCI EMERGING MARKETS ETF |
| BSE 17-Oct-2022 | Sell BLOCK | 11,841 @ 1378.65 | ISHARES INDIA SC MAURITIUS COMPANY |
| BSE 17-Oct-2022 | Buy BLOCK | 11,841 @ 1378.65 | ISHARES MSCI INDIA SMALL-CAP ETF |
| BSE 11-Oct-2022 | Sell BLOCK | 77,734 @ 1393.45 | ISHARES CORE EMERGING MARKETS MAURITIUS CO |
| BSE 11-Oct-2022 | Buy BLOCK | 77,734 @ 1393.45 | ISHARES CORE MSCI EMERGING MARKETS ETF |
| BSE 11-Oct-2022 | Sell BLOCK | 11,417 @ 1393.45 | ISHARES INDIA SC MAURITIUS COMPANY |
| BSE 11-Oct-2022 | Buy BLOCK | 11,417 @ 1393.45 | ISHARES MSCI INDIA SMALL-CAP ETF |
| BSE 19-Sep-2022 | Sell BLOCK | 72,154 @ 1431.75 | ISHARES CORE EMERGING MARKETS MAURITIUS CO |
| BSE 19-Sep-2022 | Buy BLOCK | 72,154 @ 1431.75 | ISHARES CORE MSCI EMERGING MARKETS ETF |
| BSE 19-Sep-2022 | Sell BLOCK | 10,499 @ 1431.75 | ISHARES INDIA SC MAURITIUS COMPANY |
| BSE 19-Sep-2022 | Buy BLOCK | 10,499 @ 1431.75 | ISHARES MSCI INDIA SMALL-CAP ETF |
DIVIDEND BY GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
| Ex Dividend Date | Dividend Type | Dividend |
|---|---|---|
| 07-Nov-2024 | INTERIM DIVIDEND | 12 |
| 31-May-2024 | DIVIDEND | 32 |
| 30-Jun-2023 | DIVIDEND | 32 |
| 07-Jul-2022 | DIVIDEND | 30 |
| 07-Jul-2022 | SPECIAL DIVIDEND | 60 |
| 19-Jul-2021 | DIVIDEND | 30 |
SPLIT / BONUS BY GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
